These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17471601)

  • 21. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using resources for scientific-driven pharmacovigilance: from many product safety documents to one product safety master file.
    Furlan G
    Drug Saf; 2012 Aug; 35(8):615-22. PubMed ID: 22788233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pattern and quality of scientific communications on drug safety produced by a regional pharmacovigilance center in Nepal.
    Palaian S; Ibrahim MI; Mishra P
    Pharm Pract (Granada); 2010 Jul; 8(3):179-86. PubMed ID: 25126138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data.
    Solomon C; Gröner A; Ye J; Pendrak I
    Thromb Haemost; 2015 Apr; 113(4):759-71. PubMed ID: 25502954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study.
    Donegan K; Owen R; Bird H; Burch B; Smith A; Tregunno P
    Drug Saf; 2018 Sep; 41(9):899-910. PubMed ID: 29725942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality criteria for early signals of possible adverse drug reactions.
    Edwards IR; Lindquist M; Wiholm BE; Napke E
    Lancet; 1990 Jul; 336(8708):156-8. PubMed ID: 1973481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low quality of reporting adverse drug reactions in paediatric randomised controlled trials.
    de Vries TW; van Roon EN
    Arch Dis Child; 2010 Dec; 95(12):1023-6. PubMed ID: 20551194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk management in dermatology: an analysis of data available from several British-based reporting systems.
    Gawkrodger DJ
    Br J Dermatol; 2011 Mar; 164(3):537-43. PubMed ID: 21143464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.
    Harinstein L; Kalra D; Kortepeter CM; Muñoz MA; Wu E; Dal Pan GJ
    Drug Saf; 2019 May; 42(5):649-655. PubMed ID: 30569267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.
    Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG
    Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946
    [No Abstract]   [Full Text] [Related]  

  • 36. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 37. Individual case safety reports--how to determine the onset date of an adverse reaction: a survey.
    Klepper MJ; Edwards B
    Drug Saf; 2011 Apr; 34(4):299-305. PubMed ID: 21417502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmaceutical manufacturer's perspective on reporting adverse drug experiences.
    Sullivan JW
    Am J Hosp Pharm; 1990 Jun; 47(6):1342-5. PubMed ID: 2368728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
    Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
    Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association rule mining in the US Vaccine Adverse Event Reporting System (VAERS).
    Wei L; Scott J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):922-33. PubMed ID: 26045284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.